Cholinesterase (ChE) inhibition represents the most efficacious treatment approach for
Alzheimer's disease (AD) to date. This multiple-dose study has examined the relationship …

Cholinesterase inhibitors (ChEIs) have shown positive symptomatic effects on cognition,
activities of daily living, and behavior in patients with Alzheimer's disease (AD). Rivastigmine …

Background: Rivastigmine enhances cholinergic activity and has been shown in clinical
trials to decrease the rate of deterioration in Alzheimer's disease. It remains unclear where in …

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713;
Exelon®), in patients with mild to moderately severe Alzheimer's disease was evaluated in a …

Cholinesterase inhibitors are currently the most established treatment strategy in
Alzheimer's disease. The treatment effect appears mainly to be symptomatic. Effects on …

Twenty seven patients with mild AD were enrolled in a prospective open label controlled
study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural …

In early Alzheimer's disease, which initially presents with progressive loss of short-term
memory, neurodegeneration especially affects cholinergic neurons of the basal forebrain …

Acetylcholinesterase and butyrylcholinesterase activities emerge in association with
plaques and tangles in Alzheimer's disease. These pathological cholinesterases, with …

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713), in
patients with advanced moderate Alzheimer's disease (AD) was evaluated in a 12-month …

Background: The current study aimed to compare the effects of different cholinesterase
inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and …